Related Experiment Video

Updated: Nov 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach

Sarah N Lauder1, Bart Vanhaesebroeck2, Awen Gallimore3

  • 1Division of Infection and Immunity, Cardiff University School of Medicine, SIURI, Cardiff, UK. LauderSN@cardiff.ac.uk.

British Journal of Cancer
|April 7, 2021
PubMed

Insights

Blocking PI3Kδ shows promise for solid tumor immunotherapy. Combining this with anti-LAG3 immune checkpoint blockade significantly enhanced treatment efficacy in pre-clinical models, leading to complete tumor control.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Emerging research highlights Phosphoinositide 3-kinase delta (PI3Kδ) blockade as a potential immunotherapy for solid tumors.
  • Immune checkpoint inhibitors are a growing area of cancer treatment.

Purpose of the Study:

  • To investigate the efficacy of combining PI3Kδ blockade with anti-lymphocyte-activation gene 3 (anti-LAG3) immune checkpoint blockade.
  • To evaluate this combination therapy in pre-clinical models of solid tumors.

Main Methods:

  • Utilized pre-clinical models to test a combined immunotherapy approach.
  • Administered PI3Kδ blockade in conjunction with anti-LAG3 immune checkpoint blockade.

Main Results:

  • The combination therapy demonstrated significant potentiation of PI3Kδ-based immunotherapy.
  • Complete tumor control was achieved in all mice treated with the combination therapy.

Conclusions:

  • Combining PI3Kδ blockade with anti-LAG3 immune checkpoint blockade is a highly effective strategy for solid tumor immunotherapy.
  • This combination therapy shows strong potential for future clinical applications in cancer treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K